Author(s): Byar DP
In the first Veteran's Administration Cooperative Urological Research Group (VACURG) study all stage I and II patients were assigned to radical prostatectomy and were randomized to either placebo or 5 mg diethylstilbestrol (DES) daily by mouth. Results indicated worse survival in those treated with DES in stage I, but there was no difference in stage II. In Study 2, stage I and II patients were randomly assigned to either placebo or placebo plus radical prostatectomy. An analysis based upon time to progression failed to show a significant advantage for radical prostatectomy. Both the size of the primary lesion at diagnosis and the histological grade of the tumor using the Gleason system were related to the probability of progression.
Referred From: https://www.researchgate.net/publication/16261046_VACURG_studies_of_post-prostatectomy_survival
Author(s): Huggins C, Hodges CV
Author(s): Sharifi N, Gulley JL, Dahut WL
Author(s): Keating NL, O’Malley AJ, Smith MR
Author(s): Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, et al.
Author(s): Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, et al.
Author(s): Roach M, Bae K, Speight J, Wolkov HB, Rubin P, et al.
Author(s): Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, et al.
Author(s): Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, et al.
Author(s): Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR
Author(s): van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, et al.
Author(s): Martín-Merino E, Johansson S, Morris T, García Rodríguez LA
Author(s): http://www
Author(s): De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, et al.
Author(s): Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, et al.
Author(s): Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, et al.
Author(s): Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, et al.
Author(s): Yap TA, Carden CP, Attard G, de Bono JS
